E. Peters

发表

Missed opportunities for HIV diagnosis: a three-year audit in the West of Scotland

R. Seaton, D. Brawley, A. Macconnachie, 2013, Scottish medical journal.

Hospitalised adult patients with Suspected 2009 H1N1 Infection at Regional Infectious Diseases Units in Scotland--most had alternative final diagnoses.

R. Seaton, A. Ho, R. Gunson, 2010, The Journal of infection.

Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report

M. Kieny, S. K. Fehling, T. Strecker, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A unified personal protective equipment ensemble for clinical response to possible high consequence infectious diseases: A consensus document on behalf of the HCID programme

M. Beadsworth, B. Crook, C. Evans, 2018, Journal of Infection.

Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis

F. Marra, M. Heydtmann, E. Peters, 2019, Journal of viral hepatitis.

Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005‐2016: a national database linkage study

P. Hayes, H. Innes, S. Hutchinson, 2019, Alimentary pharmacology & therapeutics.

Antiretroviral drugs in the treatment of people living with human immunodeficiency virus: experience in a south Indian tertiary referral centre.

S. Solomon, N. Kumarasamy, S. P. Thyagarajan, 2000, The Journal of the Association of Physicians of India.

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Scott M Elliott, J. Haughney, V. Libri, 2021, The Lancet.

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

J. Haughney, V. Libri, M. Kamal, 2022, The Lancet Infectious Diseases.

Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment

E. Thomson, A. Maclean, R. Gunson, 2022, Viruses.

Modelling the impact of incarceration and prison‐based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland

P. Hayes, J. Stone, P. Vickerman, 2017, Addiction.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Evaluation of the scale-up of HIV testing among people who inject drugs in Scotland in the context of an ongoing HIV outbreak.

S. Hutchinson, R. Gunson, D. Goldberg, 2021, The International journal on drug policy.

Modelling the impact of incarceration and prison-based HCV treatment on HCV transmission among people who inject drugs in Scotland

P. Hayes, J. Stone, P. Vickerman, 2017 .

Patients with hepatitis C (Redpath): a randomised controlled trial of telephone contact or offer of an incentive, in addition to a standard letter

E. Peters, S. Barclay, M. Priest, 2020, Journal of Hepatology.

Increased case‐finding and uptake of direct‐acting antiviral treatment essential for micro‐elimination of hepatitis C among people living with HIV: a national record linkage study

C. Leen, P. Hayes, S. Hutchinson, 2020, HIV medicine.

8 weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort

F. Marra, M. Heydtmann, E. Peters, 2018 .